Survival of patients taking selinesol

The drug Selinexor (Selinexor) has made great contributions to prolonging the survival time of patients. But in the final analysis, how long a patient can live depends on many factors such as the type of disease, treatment response, disease progression, and personal physical condition. In the treatment of multiple myeloma and diffuse large B-cell lymphoma, selinesol can rejuvenate tumor suppressor genes by inhibiting the nuclear export protein XPO1, thereby significantly delaying the progression of the disease and improving patient survival.

Take patients with multiple myeloma, especially those with relapsed or refractory disease who have had little effect after multiple treatments. Clinical trials have given eye-catching data: using Selinisol combined with dexamethasone, the patient's median progression-free survival (PFS) can reach about 3.7 months, and the median overall survival (OS) is as high as about 8.6 months. This is enough to prove that Seliniso has two brushes in controlling the disease. However, the specific survival time of patients depends on their sensitivity to treatment and management of side effects.

Let’s talk about diffuse large lymphomaPatients with B-cell lymphoma, especially those with relapsed or refractory disease who have failed multiple lines of treatment, selinesol has brought them new hope. Relevant studies have shown that the median progression-free survival of patients using selinesol is approximately 2.6 months, and the median overall survival can also reach approximately 9.2 months. This therapeutic effect allows patients to see more possibilities. Of course, it is still necessary to closely monitor the efficacy and adverse reactions during the treatment process and adjust the plan in a timely manner.

It is worth noting that survival time is the median value of statistics, and the specific survival time varies from person to person. Some patients may have particularly good treatment effects and have a longer survival period; while other patients may need to change their treatment plan due to disease progression or side effects. Therefore, during the treatment process, patients must communicate with their doctors regularly to evaluate the treatment effects, adjust the plan, and strive to obtain the best results.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC10435704/